Attovia Therapeutics, Inc. (ATTO)

Price$25.55Cached quoteAs of 2026-09-06 08:54 UTC

AI: Fair-priced

Price checkThe valuation looks balanced because strong funding offsets an expensive early-stage pipeline.

Using 45.58 million shares after the fully exercised offering option, the last close implies about $1.08 billion of market value. June cash and short-term government investments of $115.1 million plus $305.4 million of net offering proceeds give roughly $420.5 million after the offering, leaving about $660 million attributed to the drug pipeline before later spending. June liabilities were only $15.6 million. Cash covers about 39% of market value and management expects funding into 2030, supporting a Fair-priced verdict rather than either extreme.

Big pictureAttovia has no product profits, and research spending is rising before larger trials.

Revenue was only $1.35 million in 2025 and $0.45 million in the second quarter of 2026, from collaboration services rather than medicine sales. Net loss widened to $60.6 million in 2025 from $39.8 million in 2024; first-half 2026 net loss was $39.3 million. Operating cash use rose to $34.9 million from $26.7 million year over year. Free cash flow—cash left after operations and equipment spending—was about negative $35.3 million. This business is driven by trial results and development spending, not normal economic cycles.

Business strengthEarly itch relief data look promising, but tiny trials cannot establish lasting success.

In the early patient study, 65% of pooled chronic-pruritus patients achieved at least a four-point itch-score improvement at week four, versus none on placebo; high-itch atopic dermatitis was 44% versus 25%. A single dose also suppressed free interleukin-31, an itch-driving signaling protein, by more than 95% for at least 12 weeks, supporting quarterly dosing. However, cohorts held only 12–14 patients, effectiveness measures were exploratory, and approved rival Nemluvio already validates and competes in this pathway. The platform is promising, not proven.

What could change the storyLarger trial confirmation could justify the premium; weaker data may force more share sales.

Complete early-stage results expected in the fourth quarter of 2026 must preserve the separation from placebo, show a credible dose response, and avoid serious treatment-related side effects. Starting both ATTO-1310 mid-stage studies and first human studies of ATTO-2306 and ATTO-1091 in early 2027 would diversify the story. The offering expanded the adjusted share base from 26.0 million to 45.6 million; 4.35 million outstanding or newly granted options could add roughly 10% more. The current value assumes early benefits survive larger trials before cash runs low.

AI: News

Upsized public offeringThe enlarged stock sale funded years of trials but sharply increased the share count.

On August 6, Attovia closed its public offering of 19.55 million shares after underwriters fully exercised their additional-share option. The company raised $332.4 million before fees and approximately $305.4 million after fees, extending its stated operating runway into 2030. The adjusted share base increased about 75%, from 26.0 million before the sale to roughly 45.6 million afterward. The latest close was about 39% above the offering price, although that comparison does not prove the financing caused the gain.

Trial plans clarifiedEarly patient results supported further trials, making fuller data the next major test.

The September 2 update reiterated early ATTO-1310 evidence of rapid itch relief and confirmed that enrollment and dosing were complete. Attovia expects full early-stage results in the fourth quarter of 2026 and plans two larger studies during the first half of 2027. Research spending rose as the company prepared those programs. Shares closed about 4% higher that session, but timing alone cannot establish causation. Because ATTO-1310 remains Attovia’s only clinical-stage candidate, confirmation or failure could materially reset the pipeline’s value.

Loading local price history

Revenue

2024

2025

Net income

2024

2025

Free cash flow

2024

2025

Total cash / debt

CashTotal debt

2024

2025

2026

Financial statements

	2025	2024
Revenue	$1.4M	$0
Research & development	$471,000	$300,000
Operating expenses	$68.5M	$41.6M
Operating income	−$67.2M	−$41.6M
Operating margin	−4,974.74%	—
EBITDA	−$66.4M	−$41.2M
EBITDA margin	−4,915.19%	—
Net income	−$60.6M	−$39.8M
Net profit margin	−4,490.89%	—
Basic EPSper basic share	-$2.37	-$1.75
Diluted EPSper diluted share	-$15.42	-$12.76